



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/941,398	08/28/2001	Constance Mary John	3157.00006	6148

7590

10/06/2003

Kenneth I. Kohn  
KOHN & ASSOCIATES  
Suite 410  
30500 Northwestern Hwy  
Farmington Hills, MI 48334

EXAMINER

SCHNIZER, RICHARD A

ART UNIT

PAPER NUMBER

1635

DATE MAILED: 10/06/2003

6

Please find below and/or attached an Office communication concerning this application or proceeding.

□ NFI  
1-1/85

5801-1

# Office Action Summary

Application No.

09/941,398

Applicant(s)

JOHN, CONSTANCE MARY

Examiner

Richard Schnizer, Ph. D

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☐ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) 1-24 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_ 6) ☐ Other: \_\_\_\_

## DETAILED ACTION

### *Election/Restrictions*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claim 2, drawn to methods of providing a biologically active moiety by administering genetically modified, naturally immune privileged cells that are from one of a group of cell types from ocular tissue, classified in class 424 subclass 571. Should Applicant elect this group, a further group restriction between iris, ciliary body, retina, and corneal epithelium cells is required.
2. Claim 3, drawn to methods of providing a biologically active moiety by administering genetically modified, naturally immune privileged Sertoli cells, classified in class 424, subclass 558.
3. Claim 4, drawn to methods of providing a biologically active moiety by administering genetically modified, naturally immune privileged cells that are from one of a group of cell types from placental tissue classified in class 424 subclass 583. Should Applicant elect this group, a further group restriction between trophoblasts, decidual cells, endometrial glandular epithelial cells, and endothelial cells is required.
4. Claim 5, drawn to methods of providing a biologically active moiety by administering genetically modified, naturally immune privileged cells that are from one of a group of cell types of the immune system classified in

class 424 subclass 577. Should Applicant elect this group, a further group restriction T lymphocytes, B lymphocytes, natural killer cells, and macrophages is required.

5. Claim 6, drawn to a method of providing a biologically active moiety by administering genetically modified, naturally immune privileged Paneth cells of gastrointestinal epithelium classified in class 424 subclass 551.

Claims 1, and 7-24 link(s) inventions 1-5. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 1 and 7-24. Linking claims 1 and 7-24 will be examined as generic claims to the extent necessary to demonstrate non-patentability. Should the linking claims be found to be allowable, the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions are distinct, each from the other because of the following reasons:

The specification teaches at page 2, lines 13-25 that different types of immune privileged cells are biologically unique, and that immune privilege is a complex property mediated by different molecules from cell type to cell type. Thus different cell types are biologically unique in the way that they create their immune privileged status, and the ability of different cell types to survive allogeneic implantation will vary. Because the cells used in the various methods are biologically unique in ways that will influence their use in the claimed methods, each of the claimed methods is deemed to be unique to a given unique cell, and restriction between the methods based upon the type of cell used in the method is proper.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification and their recognized divergent subject matter, and because each invention requires a separate, non-coextensive search, restriction for examination purposes as indicated is proper.

### ***Election of Species***

This application contains claims directed to the following patentably distinct species of the claimed invention:

Applicant must elect a naturally immune privileged cell type from the following types: primary cells, immortalized cells, and stem cells. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 12-16, 20, 22 and 24 are generic.

Art Unit: 1635

Applicant must elect a biologically active moiety from the species recited in the specification and claims, i.e. insulin, factor II, factor VII, factor VIII, factor IX, factor X, vasopressin, adenosine deaminase, glucocerebrosidase, human growth hormone, erythropoietin, calcitonin, leptin, interferon alpha, interferon beta, granulocyte-macrophage colony stimulating factor, G-CSF, gangliosides, antibodies neurotrophins, neurotrophic factors, axonal growth stimulators, and neurotransmitters. It is noted that the claims also recite interleukins and cytokines, however these are considered to be genres represented by at least the species human growth hormone, erythropoietin, macrophage colony stimulating factor, and G-CSF. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 7-10, 12, 17, 20, 21, and 22 are generic.


Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Richard Schnizer, whose telephone number is 703-306-5441. The examiner can normally be reached Monday through Friday between the hours of 6:20 AM and 3:50 PM. The examiner is off on alternate Fridays, but is sometimes in the office anyway.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John Leguyader, can be reached at 703-308-0447. The official central fax number is 703-872-9306. Inquiries of a general nature or relating to the status of the application should be directed to the Patent Analyst Trina Turner whose telephone number is 703-305-3413.

  
DAVE T. NGUYEN  
PRIMARY EXAMINER

Richard Schnizer, Ph.D.